Read all the (latest) blogs from:
Australia, Austria, Belgium, Bulgaria, China, Czech Republic, Denmark, EPC, Estonia, European Union, Finland, France, Germany, Hungary, Iceland, India, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States of America
There was no error in an inter partes review decision finding obviousness in a communication system patent because the board properly relied on materials in the record in its claim construction and obviousness analysis. An inventor of a communication system failed to show any error in an IPR proceeding which found his invention obvious, the U.S. Court…
In what will be seen as a welcome development to IP owners, the Brazilian Patent Office (BRPTO) is improving the system to record IP agreements. More specifically, on 11 July 2023, the BRPTO published Ordinances 26 and 27/2023, improving the guidelines for registration of technology transfer and franchise agreements. For recordal purposes, complete agreements are…
As with many other jurisdictions the fight over Novartis’ contested Fingolimod-patent (EP 2 959 894) (the “patent-in-suit”) is raging on in Denmark. Two recent cases from June and July yielded positive results for the patent proprietor in cases against Viatris and Zentiva respectively. The cases initially begun in Denmark in the spring of 2022, where…
The Brazilian PTO (BRPTO) released, on July 20, 2023, the report “5G Technology: Patent overview in the World and in Brazil”, with an overview of 5G Standard Essential Patent (SEP) applications. It highlights that the expansion of network infrastructure in the world is an important international agenda, as published by the ITU (International Telecommunications Union)….
On 23 June 2023, the Madrid Appeal Court (Section 32) published one of the most interesting judgments coming from Spanish courts during the last few years. The first point of interest is that this is one of the first judgments handed down by the brand new “Section 32” of the Madrid Appeal Court, recently established…
On 25 July 2023, the Court of Appeal handed down its decision in Teva & Sandoz v Astellas[1] concerning the validity of Astellas’ patent to mirabegron for use in the treatment of overactive bladder (“OAB”). At first instance, Meade J had held the patent valid and infringement by the generics’ proposed acts was not separately…
Since 29.04.2023, new Russian Patent Requirements (the Requirements) have been in force. These include several amendments compared to the previous version of the requirements, including an amended provision on the rules for unity of invention. Clause 2 of the previous requirements stipulated that the requirement of unity of invention in relation to a claimed group…
A recent decision issued by the federal district court could impact medical use patents in Brazil. In an invalidity lawsuit filed by the Brazilian affiliate of Sun Pharma against Boehringer Ingelheim, Federal Judge Carvalho, sitting at the 9th Federal District Court in Rio de Janeiro, has granted a preliminary injunction ordering the Brazilian Patent and…
Introduction On 17 July 2023, the English Court of Appeal handed down its decision in a dispute between J.C. Bamford (JCB) and Manitou about the confidentiality of information disclosed in the course of litigation between JCB and Manitou relating to the validity and infringement of certain of JCB’s patents. At the heart of the confidentiality…
My British colleague has already commented brilliantly on the UK ruling in this case from the point of view of plausibility (see here). For my part, I’d like to comment the French ruling in the same case, which takes the opposite view to the UK decision. We shall see that the French position is particularly…
